BusinessTauriga Sciences Inc. to Present at European Institutional Investor Conference on June 21, 2018 in Berlin, Germany; Venue is the Representative Office of Baden-Wurttemberg in BerlinBy Nasdaq OMXApr 25, 2018, 3:02 PM UTC
BusinessTauriga Sciences Inc. Board of Directors Approves 1 for 75 Reverse Split, Reducing Its Outstanding Common Stock to Approximately 52,300,000 Shares With a Proportional Reduction of Its Authorized Common Stock to 100,000,000 SharesBy Nasdaq OMXApr 25, 2018, 2:10 PM UTC
BusinessTauriga Sciences Inc. Formally Cancels All Remaining Back-End Convertible Debentures Held by Adar Bays LLC in Connection with the $210,000 Financing Agreement from September 2017By Nasdaq OMXApr 16, 2018, 4:24 PM UTC
BusinessTauriga Sciences Inc. Increases its Stake in Crypto Currency Groestlcoin (Code: GRS); Company Now Holds 39,862 GRS UnitsBy Nasdaq OMXApr 4, 2018, 11:59 AM UTC
BusinessTauriga Sciences, Inc. Elects to Change the Name of its Recently Formed Delaware Subsidiary to: Tauriga Biz Dev Corp.By Nasdaq OMXMar 26, 2018, 12:01 PM UTC
BusinessTauriga Sciences Inc. Increases Equity Stake in Colorado Based NASDAQ Listed Biotechnology Firm Focused in the Medical Field of UrologyBy Nasdaq OMXMar 9, 2018, 3:44 PM UTC
BusinessTauriga Sciences Inc. Takes Advantage of Market Weakness and Averages Down with Purchase of an Additional $10,000 USD Worth of Crypto Currency GroestlcoinBy Nasdaq OMXFeb 2, 2018, 5:13 PM UTC
BusinessTauriga Sciences Inc. Completes its Purchase of Crypto Currency GroestlcoinBy Nasdaq OMXJan 19, 2018, 2:35 PM UTC
